Biography
Dr. Rebecca Lehmann is currently a postdoctoral researcher in the Brain Tumour group at the Children's Cancer Institute, under the supervision of Dr. Ben Rayner and Prof. David Ziegler. Rebecca graduated from a Bachelor of Biomedical Science in 2013 from the University of Adelaide with First Class Honours, and received her PhD from the University of Adelaide in 2019. During her PhD candidature, Rebecca investigated the mechanisms underlying...view more
Dr. Rebecca Lehmann is currently a postdoctoral researcher in the Brain Tumour group at the Children's Cancer Institute, under the supervision of Dr. Ben Rayner and Prof. David Ziegler. Rebecca graduated from a Bachelor of Biomedical Science in 2013 from the University of Adelaide with First Class Honours, and received her PhD from the University of Adelaide in 2019. During her PhD candidature, Rebecca investigated the mechanisms underlying the severe neurological pathology of the paediatric neurodegenerative disease, Mucopolysaccharidosis, examining the effects of increased heparan sulphate content and aberrant sulphation patterning on stem cell differentiation. In 2019, following completion of her PhD, Rebecca started as a postdoctoral researcher in the Brain Tumour Group at the Children's Cancer Institute. Her work focuses on identifying new treatments for children with the universally lethal brain tumour, Diffuse Midline Glioma, and other hard to treat childhood brain tumours.
My Grants
Perpetual IMPACT Philanthropy Grant (2023 - 2024): A better treatment for drug-resistant childhood brain cancer
Tour de Cure ECR grant (2024 - 2025): New treatments for drug-resistant BRAFV600E paediatric high-grade glioma
My Qualifications
PhD, University of Adelaide, 2015-2019
Bachelor of Science (Hons), University of Adelaide, 2013
Bachelor of Science (BiomedSc), University of Adelaide, 2010-2012
My Awards
2023 Cancer Institute NSW Travel Grant
2023 Kids Cancer Alliance (KCA) Childhood Cancer Symposium ECR Oral Presentation First Prize
2023 Australian Society for Medical Research (ASMR) National Conference EMCR Poster Award
2022 Children's Cancer Institute Research Symposium Outstanding ECR Poster Presentation Award
2021 University of Adelaide AMS/Biomedicine Publication Award
2018 Fresh Science Competition South Australian Finalist
2018 Hospital Research Foundation BioMed City Travel Award
2018 National Stem Cell Foundation of Australia Travel Award
2018 Walter and Dorothy Duncan Trust Travel Grant
2017 Australian and New Zealand Society for Cell and Developmental Biology (ANZSCDB) Outstanding Student Oral Presentation Prize
2017 Australasian Society of Stem Cell Research (ASSCR) Travel Award
2015 Matrix Biology Society of Australia and New Zealand (MBSANZ) Travel Award
2015 Australian Postgraduate Award (PhD Scholarship)
2013 University of Adelaide Molecular and Biomedical Science Honours Scholarship
My Research Activities
1. Determining the efficacy of CDK4/6 inhibitor combination treatments for Diffuse Midline Glioma
2. Identifying new treatments for BRAF/MEK inhibitor resistant paediatric brain tumours
My Research Supervision
Areas of supervision
Honours and PhD Projects currently available:
- Drug resistance in paediatric high-grade glioma
Drug resistance is a constant obstacle to developing effective treatments in paediatric high-grade glioma. This project will focus on developing novel treatments against BRAF-inhibitor resistant paediatric high-grade glioma and determining their efficacy in vitro and in vivo.
- Cell cycle inhibitors in diffuse midline glioma
The cell cycle is frequently dysregulated in diffuse midline glioma, the most lethal paediatric brain tumour. This project focuses on identifying new therapies which target cell cycle dysregulation, both in vitro and in vivo.
Currently supervising
Honours Students:
2022
Joshua Zhu
Project: Overcoming drug resistance in BRAFV600E mutant paediatric high-grade gliomas
Contact
Publications
ORCID as entered in ROS
https://orcid.org/0000-0001-6145-5971